Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant te chniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice vari ant for the treatment of infections, such as bacterial, fungal, protozoan and viral infectio ns, particularly infection caused by HIV-l or HIV-2; pain; cancers; anorexia; bulimia; asthma; Pa rkinson's disease; both acute and congestive heart failure; hypotension; hypertension; uri nary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizop hrenia, manic depression, delirium, dimentia or severe mental retardation; dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others. Antagonist s against such an 11cb splice variant and their use as a therapeutic to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infaction caused by HIV-1 o r HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; both acute and co ngestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angin a pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psych otic and neurological disorders, including anxiety, schizophrenia, manic depression, deli rium, dementia or severe mental retardation; and dyskinesias, such as Huntington's dis ease or Gilles dela Tourett's syndrome, among others, are also disclosed. Also disclosed are di agnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for det ecting mutations in the polynucleotides encoding the 11cb splice variant and for detect ing altered levels of the polypeptide in a host.
NOVEL HUMAN 11 CB SPLICE VARIANT